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Abstract
Background: Neuralgic amyotrophy (NA) is a distinct peripheral neurological disorder of the brachial plexus with a
yearly incidence of 1/1000, which is characterised by acute severe upper extremity pain. Weakness of the stabilising
shoulder muscles in the acute phase leads to compensatory strategies and abnormal motor control of the shoulder
- scapular dyskinesia. Despite peripheral nerve recovery, scapular dyskinesia often persists, leading to debilitating
residual complaints including pain and fatigue. Evidence suggests that persistent scapular dyskinesia in NA may
result from maladaptive cerebral neuroplasticity, altering motor planning. Currently there is no proven
effective causative treatment for the residual symptoms in NA. Moreover, the role of cerebral mechanisms in persistent
scapular dyskinesia remains unclear.
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Methods: NA-CONTROL is a single-centre, randomised controlled trial comparing specific rehabilitation to usual care in
NA. The rehabilitation programme combines relearning of motor control, targeting cerebral mechanisms, with self-
management strategies. Fifty patients will be included. Patients are recruited through the Radboud university medical
center Nijmegen, the Netherlands. Patients with a (suspected) diagnosis of NA, with lateralized symptoms and scapular
dyskinesia in the right upper extremity, who are 18 years or older and not in the acute phase can be included. The primary
outcome is the Shoulder Rating Questionnaire score, which measures functional capability of the upper extremity. Secondary
clinical outcomes include measures of pain, fatigue, participation, reachable workspace, muscle strength and quality of life. In
addition, motor planning is assessed with first-person motor imagery and functional magnetic resonance imaging. In a sub-
study the patients are compared to 25 healthy participants, to determine the involvement of cerebral mechanisms. This will
enable interpretation of cerebral changes associated with the rehabilitation programme and functional impairments in NA.
Discussion: NA-CONTROL is the first randomised trial to investigate the effect of specific rehabilitation on residual
complaints in NA. It also is the first study into the cerebral mechanisms that might underlie persistent scapular
dyskinesia in NA. It thus may aid the further development of mechanism-based interventions for disturbed motor
control in NA and in other peripheral neurological disorders.
Trial registration: ClinicalTrials.gov, NCT03441347. Registered on 20 February 2018.
Keywords: Neuralgic amyotrophy, Parsonage Turner syndrome, Neurorehabilitation, Upper extremity, Scapular
dyskinesia, Motor control, Peripheral nerve dysfunction, Maladaptive neuroplasticity, Physical therapy, Occupational
therapy
Background
Plasticity is a feature of the central motor system that al-
lows change in the system organisation. It enables the
development of new motor strategies in a changing en-
vironment, which can be advantageous when learning a
new skill, or when recovering from injury by adapting
with a compensatory strategy. When elements of the
motor system are damaged, for example in neurological
disorders, neuroplasticity enables patients to regain (part
of their) motor function [1, 2]. However, the plasticity is
maladaptive when changes in the central motor system
are not beneficial to functioning. Maladaptive neuroplas-
ticity can have detrimental consequences, resulting in
impaired motor function. There are indications that mal-
adaptive motor strategies can occur not only in central,
but also in peripheral nervous system disorders [3–6].
Neuralgic amyotrophy (NA) is a peripheral nervous
system disorder in which (mal)adaptive central neu-
roplasticity might be important. There are several in-
dications from clinical experience that (mal)adaptive
central neuroplasticity is involved in this disorder
[7]. However, little is currently known about the
central mechanisms in this peripheral nervous sys-
tem disorder. NA is a distinct peripheral nervous
system disorder of the brachial plexus, with a yearly
incidence ratio of 1/1000 [7, 8]. It can also be
described as an asymmetric, autoimmune inflamma-
tion of the brachial plexus and peripheral nerves. In
the acute phase, the inflammation causes damage to
the affected nerves, leading to the characteristic
acute severe upper extremity pain, multifocal paresis
(i.e. muscle weakness) with functional impairments,
and patchy areas of sensory loss. The long thoracic
nerve that innervates the serratus anterior muscle, is
affected in about 70% of patients with NA [9]. In a
substantial subset of patients (> 50%), weakness of
the serratus anterior muscle in the acute phase leads
to compensatory, abnormal positioning and move-
ment patterns of the scapula in the chronic phase.
These patients develop chronic musculoskeletal pain
in the paretic and compensating muscles, which
leads to residual complaints of decreased functional
capability of the affected upper extremity [10]. Many
patients additionally suffer from impairment of activ-
ities of daily living, fatigue and decreased participa-
tion in daily occupations [7, 10]. The abnormal
posture and movement patterns of the scapula are
referred to as scapular dyskinesia. The concept of
persisting shoulder complaints in NA is that through
its plasticity, the motor system adapts to retain
motor control of the shoulder region by forming
compensatory movement patterns in the acute phase.
After the acute phase, most of the damaged nerves
recover over time and with this recovery, the
strength of affected muscles, including the stabilising
serratus anterior muscle, can return. However, recov-
ery often does not lead to improved function be-
cause of dysfunctional coordination and instability of
the scapula. Although some patients with NA recover
well after 2–3 years, recovery is complicated in many [7,
9–12]. Residual complaints in NA are strongly correlated
with persisting scapular dyskinesia [10]. There is currently
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no proven effective causative treatment for NA [13] and
the usual care given, mostly standard physical therapy, is
ineffective and may even worsen complaints in more than
half of patients with NA [10]. The fact that scapular dys-
kinesia persists even when the peripheral nerves and
strength of the stabilising scapula muscle recover implies
that other, cerebral factors may play a role in explaining
the residual symptoms and variable recovery in patients
with NA. We introduce the concept that peripheral nerve
damage in NA may lead to adaptations in motor planning
and representations that are compensatory in the acute
phase, but lead to impaired and dysfunctional motor con-
trol in the chronic phase (see Fig. 1).
This suggested involvement of maladaptive motor
planning is illustrated by the promising results of spe-
cific rehabilitation after NA [14]. Through rehabilitation
focused on relearning motor control, which thus targets
cerebral mechanisms, patients with NA can relearn how
to correctly position and move their shoulder and arm,
which normalises scapular coordination and stability and
improves functional capability of the upper extremity. A
specific multidisciplinary and personalised rehabilitation
programme, consisting of a visit to a specialised out-
patient clinic that is followed by 8 sessions of physical
and occupational therapy over a period of 16 weeks, has
been developed at the Radboud University Medical Cen-
ter (Radboudumc) in Nijmegen, the Netherlands. This
programme combines relearning of motor control with
self-management strategies. A clinical pilot study in
eight participants showed that this rehabilitation
programme can substantially relieve complaints and im-
prove daily function at the level of activities, perform-
ance and participation. The programme was feasible, as
all patients with NA were able to complete the entire
programme. The number needed to treat was low, with
75% of the participants improving on the primary out-
come measures [14].
Taken together, the available evidence strongly sug-
gests that maladaptive motor planning plays a role in
long-term symptoms and disability in NA. Indirect evi-
dence includes the presence of persistent scapular dys-
kinesia despite peripheral nerve recovery and muscle
strength, and the fact that rehabilitation focused on
relearning motor control can normalise scapular move-
ments and positioning. However, at this time, there is no
direct evidence for (mal)adaptive cerebral neuroplasticity
in NA. Despite the high incidence of NA (1/1000 a year)
[8] and the presence of debilitating residual complaints
[10], there are no randomised controlled trials (RCTs)
investigating rehabilitation therapies targeting the re-
sidual complaints in NA. The NA-CONTROL study is
an RCT designed to fill this gap; it compares the effect
of a rehabilitation programme specifically designed for
the residual complaints in this disorder to usual care
in patients with NA. Additionally, the trial will com-
bine clinical measures with measures derived to assess
motor planning and representations in the central
motor system, to provide mechanistic insights into
Fig. 1 Cerebral reorganisation and rehabilitation after peripheral dysfunction in neuralgic amyotrophy. Schematic presentation of the concept
that peripheral nerve damage leads to adaptations in motor planning that are compensatory in the acute phase, but lead to impaired motor
control in the chronic phase. Neuralgic amyotrophy (NA) is an acute autoimmune inflammation of the brachial plexus, characterised by acute
severe upper extremity pain and multifocal paresis. Many patients with NA develop abnormal motor control of the scapular region, scapular
dyskinesia, which persists even after peripheral nerve recovery. This suggests that persistent scapular dyskinesia in NA may result from maladaptive
neuroplasticity. Rehabilitation focused on relearning motor control, targeting cerebral mechanisms, can improve scapular movement and positioning,
indicating that the impaired motor planning can be restored. This figure includes images that are adapted from Nervous system diagram licensed
under the Creative Commons Attribution-Share Alike 4.0 International license, authored by Jordi March i Nogué and William Crochot
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how the rehabilitation programme could change cen-
tral motor system plasticity.
Objectives
Primary objectives
The primary objective of this study is to determine the
effect of a specific rehabilitation programme that com-
bines relearning of motor control by targeting cerebral
mechanisms with strategies to improve self-manage-
ment, on functional capability of the upper extremity
compared to usual care in patients with NA.
Secondary objectives
The secondary objectives of this study are:
 To evaluate whether this rehabilitation programme
results in improvements in a range of domains,
including but not limited to scapular dyskinesia,
participation, quality of life and personal factors
such as pain and fatigue, compared to usual care in
patients with NA.
 To assess the longer term (17 weeks post treatment)
effects of the rehabilitation programme on a variety
of outcomes, including but not limited to functional
capability of the upper extremity, participation,
quality of life and personal factors such as pain and
fatigue.
 To determine the effect of this rehabilitation
programme on cortical motor planning and
representations compared to usual care in patients
with NA.
Methods
Study description
The NA-CONTROL study is the first RCT to investigate
treatment for residual complaints in neuralgic amyotrophy.
It additionally investigates a relatively unexplored concept
(i.e. the role of (mal)adaptive cerebral neuroplasticity in a
disorder of the peripheral nervous system) and employs
techniques (including functional magnetic resonance im-
aging (MRI)) that have not yet been used to study the under-
lying cerebral mechanisms in NA. This study is conducted
at the Donders Institute for Brain Cognition and Behaviour
and the departments of Rehabilitation and Neurology of the
Radboudumc in Nijmegen, the Netherlands.
The effect of a rehabilitation programme on functional
capability and motor planning of the upper extremity will
be compared to that of usual care in this two-arm, single-
centre, open-label RCT. The intervention group will re-
ceive a specific 17-week multidisciplinary rehabilitation
programme at the Radboudumc outpatient clinic, focused
on relearning motor control and self-management (see
“Intervention” for more information). The usual care
group will first receive usual care for a 17-week period,
before entering the rehabilitation programme.
Patients in both groups will be assessed in a single session
at baseline. At the end of the baseline measurement,
patients will be randomised into the intervention or usual
care group (see “Randomisation” for more information).
After the first 17weeks of treatment (i.e. rehabilitation
programme or usual care), both groups will be assessed in a
second session (at 18weeks post baseline). After this second
assessment, the group that initially received usual care will
then follow the specific rehabilitation programme. After
completing the 17-week rehabilitation programme, the usual
care group will be assessed a third time (at 36weeks post
baseline). All patients will be asked to fill out several ques-
tionnaires by e-mail 17weeks after completing the rehabili-
tation programme. This follow up will be at either 36weeks
(intervention group) or 54weeks (usual care group) post
baseline. Figure 2 provides a flow chart of the study design.
Sub-study
The baseline measurements of all patients with NA who are
assessed for the randomised controlled trial described in this
publication (see Fig. 2) will be used for a sub-study. Patients
with NA will be compared to 25 age-matched and sex-
matched healthy controls in this sub-study. The healthy
controls are assessed in a single session. The primary object-
ive of this sub-study will be to determine if patients with
NA have altered cerebral activity related to motor planning
of their affected arm, compared to healthy controls and
compared to their non-affected arm. This sub-study is im-
portant for the interpretation of the secondary objective (the
effect of this rehabilitation programme on cortical motor
planning and representations), to provide information about
which cerebral changes from the rehabilitation programme
are associated with functional impairments in NA.
Study population
NA is more prevalent in men than in women, with an in-
cidence ratio of 2:1, and can affect people of all ages. NA
has an idiopathic form with a median age of onset around
40 years and a hereditary form with a median age of onset
of about 28 years [7, 9]. Patients 18 years or older, with ei-
ther form of NA can participate in the study.
Number of participants and sample size calculation
In total, 50 patients with NA will be recruited for partici-
pation in this study. The required sample size was calcu-
lated from the results from the pilot study on the effect of
the rehabilitation programme [14]. The improvement in
functional capability of the upper extremity measured
with the Shoulder Rating Questionnaire, Dutch Language
Version (SRQ-DLV) was used for this sample size calcula-
tion. With a conservative standardised effect size of 0.29
(improvement in SRQ-DLV [14]), power of 0.90 and two-
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tailed testing (α = 0.05), we calculated a required sample
size of 42 patients. Assuming 20% dropout or non-compli-
ance, we need to include 50 patients with NA.
The Radboudumc hosts the national referral centre
and the only expert multidisciplinary outpatient clinic
for patients with NA in the Netherlands. Each year
around 400 new patients with NA are seen, most re-
ferred by Dutch neurologists or general physicians. Of
these 400 patients, about 40% are estimated to be eli-
gible for inclusion (see “Inclusion criteria”). We there-
fore expect to be able to recruit sufficient patients with
NA for this study within the 2-year inclusion period.
Inclusion criteria
The treating rehabilitation physician or his/her physician
assistant will judge whether a potential participant meets
the inclusion criteria. In order to be eligible to partici-
pate in this study, a participant must meet all of the fol-
lowing criteria:
1. Diagnosis (suspected) of NA
Initially, the (suspected) diagnosis of NA will be
deduced from the information in the referral letter
from the patient’s referring general physician or
neurologist. If any uncertainty about the diagnosis
remains, the rehabilitation physician or his/her
physician assistant will contact the referring
physician and/or patient. All patients will visit the
specialised outpatient clinic, where the diagnosis
will be either confirmed or discarded.
2. NA predominantly present in the right upper
extremity
3. Being in the subacute or chronic phase of NA (i.e.
no inflammation of the plexus, in practice, > 8
weeks after attack onset)
4. Presenting with scapular dyskinesia
5. Age ≥ 18 years
6. Right-hand dominance (as indicated with an
Edinburgh Handedness Inventory (EHI) score > + 40)
7. Able to provide informed consent
Exclusion criteria
For the patients with NA, the treating rehabilitation phys-
ician or his/her physician assistant will judge whether a
potential participant meets one or more of the exclusion
criteria. A potential participant who meets any of the fol-
lowing criteria will be excluded:
1. Prior NA attacks of the lumbosacral plexus or
the left upper extremity
Baseline measurement
Usual care group (n = 25) Intervention group (n = 25)
Randomization
Neuralgic amyotrophy patients (n = 50)
Usual care Rehabilitation program
Rehabilitation program
2nd outcome measurement
Post-intervention follow-up
Post-intervention follow-up
0 wks
18 wks
36 wks
54 wks
Outcome measurement Outcome measurement
Fig. 2 Flowchart of the study design: 50 neuralgic amyotrophy patients will be included. After the baseline measurement, participants are randomised into either
the intervention group or the usual care group (1:1 ratio). After the first 17-week treatment period, both groups will undergo the first outcome measurement. The
usual care group will then receive the 17-week rehabilitation program, after which they will undergo the second outcome measurement. Participants in both
groups will complete a follow up from home 17weeks after completing the rehabilitation program. Wks, weeks
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2. Previous participation in the specific rehabilitation
programme offered at the Radboudumc or the
rehabilitation centre KINOS
3. Other neuromuscular disease affecting the shoulder
girdle
4. Central nervous system disorder or neurological
disorder (e.g. Parkinson disease, stroke etc.)
5. Pre-existing (bio)mechanical constraints of the
shoulder girdle
6. A history of or recent periarticular fractures of the
shoulder
7. Past surgery of the shoulder
8. Depressive mood disorder, as indicated by a score >
5 on the Beck Depression Inventory Fast Screen
(BDI-FS)
9. Severe comorbidity
10. Ongoing participation in another scientific study
that might interfere with the current study
Exclusion criteria for undergoing MRI are:
1. Pregnancy (current or planned within the study
period)
2. The presence of metal parts that cannot be
removed, in or on the upper body (including
plates, screws, aneurysm clips, metal splinters,
piercings, medical plasters or ossicle prosthesis
but with the exception of dental fillings or
crowns)
3. The presence of an electric implant (e.g. pacemaker,
neurostimulator, insulin pump)
4. History of brain surgery
5. Claustrophobia
6. Epilepsy
Participant selection and enrolment
Figure 3 provides a flow-chart of the recruitment,
consent and other procedures of patients in the NA-
CONTROL study.
Identifying potential participants All patients with
NA that are newly referred to the Muscle Center of
the Radboudumc during the study inclusion period
will be checked for eligibility (i.e. meeting inclusion
criteria 1–5) by a member of the treatment team
through evaluation of the referral information. Eligible
patients are informed about the NA-CONTROL study
and their eligibility by post. At least a week after this
notification letter is sent, a member of the treatment
team will contact the patient to ask for his/her
consent to be contacted by the coordinating re-
searcher. Patients who express interest and provide
consent will receive the extensive trial information
package by e-mail.
Consenting participants The coordinating researcher
will contact patients who consent 7–14 days after the ex-
tensive trial information has been sent. After providing
further clarification if needed, the coordinating re-
searcher will state the inclusion and exclusion criteria. If
the patient meets the inclusion and exclusion criteria,
the researcher will ask the patient for oral consent and
the baseline measurement will be scheduled.
Written informed consent will be obtained by the
coordinating researcher at the research location. prior to
the start of the baseline measurement. All participants
will receive a copy of the signed informed consent form.
The original signed informed consent forms will be kept
at the study site. After written informed consent is ob-
tained, the patient’s hand dominance will be determined
using the Edinburgh handedness inventory (EHI) [15]
and the patient will be screened for signs of depressive
mood disorder using the Beck Depression Inventory-Fast
Screen (see “Inclusion criteria”, “6” and “Exclusion cri-
teria”, “8”, respectively).
Patients’ participation will be noted in their medical
chart. As per national regulations, all participants’ gen-
eral practitioners will be notified of their participation.
Ineligible and non-recruited patients A patient’s de-
cision to decline participation will in no way affect
their treatment at the Radboudumc. This is clearly
communicated to patients during all contacts. For
patients who are not eligible, who express that they
are not interested in participation or who do not
meet all inclusion and exclusion criteria, the usual
procedure is followed; they will be put on the regu-
lar waiting list for a consultation at our expert out-
patient clinic. The content of the rehabilitation
programme is the same for patients that participate
in the trial as for those that receive the rehabilita-
tion programme outside the study.
Outcomes
See Table 1 for an overview of all outcome measures
and their corresponding collection time points.
Primary outcome
Functional capability of the upper extremity The pri-
mary outcome measure for the clinical part of the RCT is
the change in SRQ-DLV score from baseline to post
intervention. The SRQ-DLV is a reliable and validated
questionnaire measuring functional capability of the shoul-
der, arm and hand [16] and has been shown to be sensitive
to (changes in) functional capability of the shoulder in
patients with NA [14].
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Secondary outcomes
Secondary outcome measures are divided into
clinical measures and measures related to motor
planning (see below).
Clinical The secondary clinical outcome measures
cover multiple domains of the International Classifi-
cation of Functioning, Disability and Health [17]:
A. Activities and function: these will be assessed by
administration of the following additional
questionnaire
1. Disability of Arm, Shoulder and Hand (DASH)
– The DASH questionnaire measures the
functional capability of the affected upper
extremity and has good clinimetric
properties [18].
B. Personal factors: fatigue, pain, self-efficacy and
patient activation are assessed using the following
questionnaires:
1. Checklist individual strength - subscale fatigue
(CIS-fatigue)
– The CIS-fatigue measures experienced
fatigue [19].
2. McGill Pain Questionnaire (MPQ)
– The MPQ measures the pain experienced.
It assesses the nature, intensity, location,
course and effect of the pain on daily
life [20].
Referral physician/
specialist suspected NA
Neurology
outpatient clinic
Rehabilitation
outpatient clinic
Eligibility check (based on
referral information)
Informative letter to patient
Triage
Neurology &
Rehabilitation
outpatient clinics
Phone call member
treatment team
Information package to
patient
Phone call researcher
check in- & exclusion
Informed consent
+
Baseline measurements
Rehabilitation
program
Usual care
Outcome
measurement
Outcome
measurement
2nd outcome
measurement
Follow-up
from home
Follow-up
from home
Rehabilitation
program
Inclusion and
exclusion criteria
No/
Exclusion
No/
Exclusion
No/
Exclusion
No/
Exclusion
NA = neuralgic amyotrophy
Randomisation
Fig. 3 Flow-chart of patient recruitment, consent and other procedures of the study. NA, neuralgic amyotrophy
Lustenhouwer et al. Trials          (2019) 20:482 Page 7 of 17
Table 1 Standard protocol items: recommendation for interventional trials (SPIRIT) figure: schedule of enrolment, intervention and
assessments during the trial. t5 is only applicable for patients in the usual care group. Patients in the usual care group start with the
rehabilitation programme after the outcome measurement at t4. For this group, t1, t2 and t3 take place after t4. Abbreviations: 3D: 3
dimensional; BDI-FS: Beck depression inventory – fast screen; CIS-fatigue: checklist individual strength – fatigue; COPM: Canadian
occupational performance measure; DASH: disability of arm, should and hand; EHI: Edinburgh handedness inventory; HLJT: hand
laterality judgment task; KVIQ-10: kinesthetic and visual imagery questionnaire-10; MPQ: McGill pain questionnaire; MRI: magnetic
resonance imaging; NA: neuralgic amyotrophy; NENS: neuromotor encoding in neuromuscular scapular dyskinesia; PAM: patient
activation measure; PSEQ: pain self-efficacy questionnaire; SAE: serious adverse event; SEPECSA: self-efficacy for performing energy
conservation strategies assessment; SF-36: short-form 36; SRQ-DLV: shoulder rating questionnaire – Dutch language version; USER-P:
Utrecht scale for evaluation of rehabilitation – participation
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3. Self-efficacy for performing energy conservation
strategies assessment (SEPECSA)
– The SEPECSA assesses how the patients perceive
their ability to apply energy conservation
strategies to their daily lives [21].
4. Pain self-efficacy questionnaire (PSEQ)
– The PSEQ assesses the confidence that people
with ongoing pain have in performing activities
while being in pain [22].
5. Patient activation measure (PAM)
– Patient’s activation with regard to their
health and disease is assessed using the PAM.
The PAM measures knowledge, skills and
confidence in managing one’s own health
and/or disease [23].
C. Participation: participation is assessed using the
following measures:
1. Utrecht scale for evaluation of rehabilitation-
participation (USER-P)
– The USER-P is used to evaluate the
effect of outpatient rehabilitation on
participation [24].
2. Canadian Occupational Performance Measure
(COPM)
– The COPM is used to evaluate occupational
performance and satisfaction with performance
of the most important daily occupations
identified as problematic by the patient. It thus
assesses occupational participation [25]. The
COPM is administered during the first and last
sessions of the specific rehabilitation programme
[14]. These assessments will serve as a pre-
intervention and post-intervention comparison
within patients with NA who underwent the
experimental intervention.
D. Body functions: within the body functions domain,
we will assess the reachable workspace and several
muscles/muscle groups
1. 3D-reachable workspace
– Reachable workspace is an objective measure
of upper extremity impairment [26]. It is
quantified by the relative 3D surface area
representing the portion of the unit
hemisphere that is covered by the hand
movements made during a standardised
movement protocol [26]. The movement
protocol covers cardinal movements of the
shoulder and is performed in front of the
Microsoft Kinect sensor-based reachable
workspace analysis system [26].
2. The following strength measurements will be
performed to determine maximal force exerted with
several muscles/muscle groups on both sides (left
and right upper extremity)
– The serratus anterior muscle measured using the
MicroFET2®, digital manual muscle
dynamometer, with the arm lifted to shoulder
level, in the scapular plane while
i. Reaching with the arm extended
ii. Reaching with a flexed arm (elbow at 90°).
– Rotation of the shoulder measured using the
MicroFET2®, digital manual muscle
dynamometer, with the arm at 0° anteflexion,
elbow flexed at 90° and thumb pointing upwards
i. Endorotation
ii. Exorotation.
– Hand grip measured using the Jamar® Hydraulic
Hand dynamometer, with the arm at 0°
anteflexion, elbow flexed at 90° and straight
wrist.
– Pinch grip measured using the Baseline® LiTE
Hydraulic Pinch Gauge with the arm at 0°
anteflexion and elbow flexed at 90°. The pinch
gauge is held between the index finger (top) and
thumb.
– Key grip measured with Baseline® LiTE
Hydraulic Pinch Gauge, with the arm at 0°
anteflexion, elbow flexed at 90°. The pinch gauge
is held between the thumb (top) and index finger
(bottom).
E. Quality of life: quality of life will be assessed using
the Short-Form 36 (SF-36)
– The SF-36 assesses experienced health and
health-related quality of life [27].
Motor planning Motor planning will be assessed using
a motor imagery task during which functional MRI signal
is recorded. Motor imagery involves mental simulation of
a movement, without actual execution of that movement.
It can be used as a tool to generate cortical motor states
without movement production. As is evident by the pres-
ence of scapular dyskinesia, peripheral motor control is al-
tered in NA. With motor imagery, changes in central
motor control can be assessed, while controlling for alter-
ations in peripheral factors. Empirical evidence shows that
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first-person motor imagery tasks are sensitive to motor
control variables and use central neural mechanisms in-
volved in action planning [28–30]:
A. Motor imagery task-based functional MRI
– Changes (as the result of rehabilitation and as the
result of NA (assessed in the sub-study) in the
neural mechanisms underlying motor planning and
representations will be quantified by changes in the
magnitudes of mean functional MRI signal, blood-
oxygen-level-dependent (BOLD) activity associated
with motor imagery during the Hand Laterality
Judgment task (HLJT) (see “B”).
– Analyses of the functional MRI data will primarily
be focused on the following brain regions: the
extrastriate body area, the posterior parietal cortex
in the intra-parietal sulcus region, and the precentral
and postcentral gyri. These a priori regions of
interest for analysis of functional MRI magnitude
differences are chosen based on previous research
using the same motor imagery task [1, 28, 30–32].
Additionally, we will employ a whole brain
exploratory analysis of functional changes in NA
outside these canonical motor imagery regions (see
also “Exploratory outcomes”).
– Participants’ respiration will be recorded during the
functional MRI scan to be able to control for noise
introduced in the data.
B. Performance on the motor imagery task
– The HLJT [33] assesses central representations and
planning of movements involving the upper
extremity. Participants are asked to judge the
laterality of line drawings of hands. The hands vary
in laterality (left or right), view (palmar or dorsal)
and degree of rotation (rotated − 135°, − 105°, − 75°,
− 45°, 45°, 75°, 105°, 135° from the upright position).
Participants are instructed to use their own hands as
reference (i.e. imagine moving their upper extremity
to match the hand shown on screen), without
actually moving their upper extremity. As
participants perform this task in the MRI scanner,
they cannot rely on visual information to perform
the task. The task consists of 32 blocks of 8 trials.
The inter-trial interval ranges from 2000 to 3000 ms.
Before each block, participants are instructed to
place their hands in one of four positions: both
hands with palms facing up, both hands palms
facing down, one hand palm up (left/right) and one
hand palm down (right/left). With this
manipulation, participants use of first-person motor
imagery can be checked through assessment of the
posture effect: when using first person motor
imagery, participants are faster for stimuli with a
view that is congruent with the current posture of
their own hand than for stimuli with a view that is
incongruent with the posture of their hand [28].
First-person motor imagery use can further be
corroborated by the effect of orientation:
participants are faster for medially oriented stimuli
that are associated with biomechanically easy
movements towards the body midsagittal plane, than
for laterally orientated stimuli, that are associated
with biomechanically difficult movements away from
the body midsagittal plane [28]. Participants are to
report whether the hand drawing on display
presented a left or right hand by pressing the
corresponding button with their left or right foot.
– Behavioural performance on this task is evaluated by
means of response times (i.e. time from stimulus
onset to button press) and error rates (i.e. the
number of incorrect trials divided by the total
number of valid trials).
– During the task, alertness is monitored with an eye
monitor and bipolar surface electromyography
(EMG) over both thumbs is performed, to monitor
muscle activity indicative of hand movements and
exclude the influence of overt movements.
Other parameters
Some measures will be collected to describe the study
population and if applicable, to correct for possible con-
founding effects:
A. Demographics: demographic data that will be
collected includes age, sex and education level
B. NA characteristics: data on several characteristics
of patients with NA will be collected. These include
disease onset and duration, history of prior attacks
and use of medication. Other characteristics may
include, presence of atrophy, pattern of motor
paresis, mechanical sensitivity of the plexus to pain,
maximal severity of paresis during the attack and
duration of primary pain.
C. Comorbidity: relevant information on comorbid
conditions and medication use will be collected.
D. Motor imagery ability: there are individual
differences in motor imagery ability [34]. As a
subject’s ability to imagine movements might affect
his/her performance on the motor imagery tasks in
this study, motor imagery ability is assessed with
the short version of the Kinesthetic and visual
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imagery questionnaire (KVIQ-10). The KVIQ-10
assesses the clarity of the image (visual), and the
intensity of the sensations (kinesthetic), that the
subject is able to imagine from the first-person
perspective [35].
Exploratory outcomes
In addition to its primary and secondary outcomes, the
NA-CONTROL study includes some exploratory out-
come measures that have not been used before to study
NA or any similar patient populations. They were added
to the study to gain additional insight in the underlying
mechanisms of the residual complaints in this disorder.
Cerebral (re)organisation Cerebral (re)organisation in
NA will further be explored by means of additional MRI
scans. For this purpose, functional and high-resolution
anatomical images of the whole brain will be acquired
on a 3 T Siemens whole body scanner at the Donders
Centre for Cognitive Neuroimaging. An eye monitor will
be utilised during the MRI scanning to monitor alert-
ness. In addition to the secondary MRI outcome (i.e. the
HLJT motor imagery task-based functional MRI signal),
two different neuroimaging markers of cerebral organ-
isation will be used:
A. Functional (re)organisation in rest
– Participants will be asked to lie still, think of
nothing in particular and look at a fixation cross
while 7 min of resting-state functional MRI data
are obtained.
– Changes in functional activity and connectivity of
several brain areas and cognitive resting-state
networks (including the sensorimotor, fronto-
parietal and executive control networks) will be
analysed primarily with independent component
analysis techniques on resting-state functional MRI
data [36].
B. Structural (re)organization
– Changes in cerebral grey and white matter will
be assessed using structural brain analysis based
on anatomical T1-weighted MRI scans. We will
perform voxel-based morphometry, a validated
and fully automated technique for computational
analysis of differences in global and local grey
and/or white matter volume [37].
 As this part of the study is exploratory,
analyses of the resting-state functional MRI
data and structural MRI data will not be
focused on a priori regions or networks of
interests. In addition to the resting-state
functional MRI and structural MRI scans, a
new first-person motor imagery is employed
to further assess motor planning and
representations.
C. Neuromotor Encoding in Neuromuscular Scapular
dyskinesia task (NENS-task)
– This first-person motor imagery task was
specifically designed to investigate the impact of
central motor planning in the clinical
phenomenon of scapular dyskinesia. Participants
are asked to imagine making pointing
movements with their left or right elbow (novel
movement) or finger (trained movements)
towards targets shown on a computer screen,
and to indicate with a right-foot button press
when they have finished imaging the movement
(i.e. when they have reached the target with the
specified body part). Performance is evaluated by
means of response times. Response time is
defined as the time from stimulus onset to
button press.
– For the NENS task, bipolar EMG of both
serratus anterior muscles is used, to monitor
muscle activity and exclude the influence of
overt movements. The NENS task is performed
outside the MRI environment, seated behind a
computer screen.
Other exploratory outcomes Position and orientation
of the scapula: the 3D position and orientation of the
scapula will be explored with a new measurement proto-
col. Anatomical locations for marker placement will be
identified through manual palpation by a trained assessor
(RL). These anatomical locations correspond to a thor-
acic reference plane (top and bottom of sternum, spine
(vertebrae C7, T8), and three bony landmarks of the
scapula (the angulus inferior, trigonum spinae and angu-
lus acromialis) [38] at three levels of anteflexion (0°, 90°
and 120°). Marker locations will be captured with 3D-
photography at the Radboudumc’s 3D-photography la-
boratory. Subsequent analyses will provide the position
and orientation of the scapula relative to the thoracic ref-
erence coordinate system.
Randomisation and blinding
Patients with NA will be randomly assigned to either the
experimental intervention or to the usual care in a 1:1
ratio. Patients are randomized using a Good Clinical
Practice (GCP)-compliant system (Castor Electronic
Data Capture), which employs stratified, variable block
randomisation. To prevent uneven distribution of cer-
tain characteristics across groups, randomisation will be
stratified according to two factors: sex (male/female) and
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age (4 blocks: 18–30, 30–42, 42–54, > 54 years). Ran-
domisation will be performed on site (at the Donders In-
stitute for Brain Cognition and Behaviour, Centre for
Cognitive Neuroimaging) after the participant has com-
pleted the baseline measurement (see Table 1).
Due to the project design, it is not possible to blind
participants or the assessor. Participants will inevit-
ably know whether they are receiving the rehabilita-
tion programme or usual care. The assessor cannot
be blinded either, for multiple reasons: all assessments
are performed by a single assessor; as the number of
assessments differs across groups, the assessor will
know which participant belongs to which group; as
the rehabilitation programme takes place at the asses-
sor’s workplace facility, the assessor could be un-
blinded on encountering a participant visiting the fa-
cility for treatment.
Withdrawal procedures
Participants can choose to withdraw their consent and
leave the study at any time, without specifying the rea-
son. No additional assessments will be obtained after a
subject withdraws. Data that have been collected up
until that point will be used for analyses. Participants
have consented to this as part of the original informed
consent. Patients that want to withdraw from the study
can continue with the rehabilitation programme outside
the trial if they wish to do so.
The investigator or a member of the treatment team
can decide to withdraw a subject from the study for ur-
gent medical reasons. Patients with NA who have a re-
current attack during their participation will be
withdrawn from the study.
If a patient is withdrawn from the study before their
visit to the expert outpatient clinic, they are asked to
come to the Rehabilitation or Neurology outpatient
clinic for a single interdisciplinary visit, to confirm their
diagnosis of NA and provide treatment advice as usual.
Patient retention
Patient retention is promoted in several ways. When
participating in the specific rehabilitation programme,
the patient is in regular contact with the Radboudumc
treatment team (i.e. first five weekly visits, followed by
two biweekly visits and two monthly visits over a 17-
week period). Patients in the usual care group will be
contacted at least twice during the 17-week control
treatment period. The coordinating researcher will con-
tact them by phone to inquire how the patient is and to
remind them of the dairy in which they keep track of
the care and/or treatment they have received. Both
groups will be reminded about the post-treatment mea-
surement(s) in the week prior to the upcoming visit.
Intervention
The intervention under investigation is the rehabilitation
programme developed and offered at the Radboudumc.
This experimental intervention is compared to the usual
care for NA in the Netherlands.
Experimental intervention
The experimental intervention is a 17-week specific re-
habilitation programme. The programme starts with a
visit to the specialised outpatient ‘Plexus clinic’ in week
1. During this visit, the patient is examined by a multi-
disciplinary team consisting of a rehabilitation physician,
neurologist, physical therapist and occupational therap-
ist. This specialised multidisciplinary team analyses the
problems of the patient and provides a diagnosis and
treatment advice. This treatment advice is implemented
through four weekly sessions in weeks 2–5, two biweekly
sessions in weeks 6–9 and two monthly sessions in
weeks 10–17 (see Fig. 4 for an overview). Each of the
eight treatment sessions involves one hour of occupa-
tional therapy and one hour of physical therapy. When
needed, interdisciplinary strategies are employed.
The model depicted in Fig. 5 forms the basis for the
rehabilitation programme. This model consists of several
components that are addressed during the intervention
programme. The programme combines strategies of
relearning motor control to normalise scapular stability
and coordination [39], with strategies focused on self-
management, including energy conservation [40], to en-
able daily occupations. The focus and extent to which
components are addressed are adjusted to accommodate
individual patients’ needs. For a full description of the
rehabilitation programme, see IJspeert, Janssen [14] and
van Eijk, Groothuis [7].
Usual care (control group)
The 25 patients with NA in the control group will re-
ceive usual care for 17 weeks. The usual care may vary
for each individual, and may even consist of no treat-
ment at all. Patients are asked to keep a diary during this
period, in which they will report on the care/treatment
they receive, including the type of care (e.g. physical or
occupational therapy, acupuncture), number of sessions
and composition of the care (e.g. strength training, aer-
obic training, massage). After 17 weeks, patients in the
usual care group will start with the 17-week rehabilita-
tion programme at the Radboudumc as described above.
Co-interventions
During the experimental intervention, co-interventions
can be employed if needed. These co-interventions may
include but are not limited to analgesics and steroid
medication. While undergoing the experimental inter-
vention, patients are asked to refrain from seeking
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additional treatment for the upper extremity outside the
scope of the rehabilitation programme (e.g. additional
therapy or care), unless this is discussed with the
treating physician in advance. The use of any co-inter-
ventions will be registered.
Study participants are not allowed to participate in any
other scientific study that might interfere with their par-
ticipation in the NA-CONTROL study (from signing in-
formed consent to completing the follow up from
home).
Post-trial care
If deemed necessary by the treating clinician and de-
sired by the patient, the treatment can be extended
after the nine sessions that are part of the experimen-
tal intervention.
Data collection and management
Data collection
Data will be collected as described under “Outcomes”.
The assessor (the coordinating researcher) conducting
the measurements is trained in collecting all measures
that are obtained during the measurement protocol (i.e.
operating MRI systems, applying bipolar EMG surface
electrodes, conducting force measurements, palpating
bony landmarks of the scapula and trunk, etc.).
Data management system
Most data are collected through laboratory-based meas-
urement systems, or entered directly into the electronic
case report form (CRF) in a GCP-compliant electronic
data management system (Castor EDC, www.castoredc.
com). This system utilises a log system with an auto-
mated audit trail. The Delegation of Responsibilities Log
will identify all individuals responsible for data collection
and handling, and management of the database.
A data management plan, detailing location of and ac-
cess to study data and the code list, method of coding,
back-up, locking and archiving of data, code list and
analysis files has been submitted to and approved by the
Board of Directors of the Radboudumc.
Statistics and data analysis
Proposed analysis
All continuous variables will be summarised as the num-
ber of (missing) observations, mean, standard deviation,
median and range. Categorical variables will be sum-
marised as the number of (missing) observations and
number and percentage in each category. This will be
done separately for each time point (baseline, outcome
measurement(s) and follow up) and for the change from
baseline for each intervention group.
The primary clinical outcome (SRQ-DLV score) and
most other clinical outcomes are linear or quasi-linear.
Fig. 4 Overview of assessments and treatment for the intervention group (a) and the usual care group (b). A single treatment session consists of
1 h of physical therapy and 1 h of occupational therapy. BM, baseline measurement; PP, visit to out-patient plexus clinic; TS, treatment session;
OM, outcome measurement; F-U, follow up
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Group differences in the effects of the intervention on
primary and secondary outcome measures and the influ-
ence of possible effect modifiers will be investigated
using generalised estimated equations analysis. If neces-
sary, analyses will be adjusted for group differences in
functional capability of the upper extremity (SRQ-DLV
score), age and sex at baseline. Data will be analysed ac-
cording to the intention-to-treat principle. Data will be
appropriately transformed if necessary, to satisfy model-
ling assumptions. Prior to locking of the data, a statis-
tical analysis plan will be drawn up and approved by a
statistician and the principal investigator.
Missing data
Throughout data collection, measures will be taken
where possible to minimise the occurrence of missing
data. These measures include those mentioned under
“Patient retention” and clear communication with indi-
viduals involved in data collection.
Once data collection is complete, the extent of missing
data will be evaluated. Any patterns in missing data will
be explored, especially in relation to the intervention
groups. Missing data will be imputed if necessary and if
possible.
Monitoring
Data monitoring
As this study has a negligible risk classification it
does not require a data monitoring committee. The
study will be monitored by an independent, certified
monitor according to the Netherlands Federation of
University Medical Centres guidelines for monitoring
of clinical studies. The frequency and extent of study
monitoring is defined in a monitor plan that has been
submitted to and approved by the Board of Directors
of the Radboudumc.
(Serious) adverse events
All adverse events (AEs) reported spontaneously by the
subject or observed by the investigator or the treatment
team will be recorded. All AEs will be followed until
they have abated or until a stable situation has been
reached. Depending on the event, follow up may require
additional tests or medical procedures as indicated and/
or referral to the general physician or a medical
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Fig. 5 Treatment model with the components addressed during the rehabilitation programme. Issues in the outer two circles (External factors,
Activity and Participation) form the main focus of the occupational therapy sessions. During the physical therapy sessions, the main focus is on
improving body functions. All other components (i.e. disease knowledge, fatigue, pain, behaviour and self-efficacy and self-management) are
addressed during occupational and physical therapy. This is accomplished through conveying knowledge of neuralgic amyotrophy and adaptation of
behaviour related to functioning in daily life. Reproduced with permission from IJspeert et al. NeuroRehabilitation 2013;33:657–665 [14]
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specialist. All serious adverse events (SAEs) will be re-
ported to the accredited medical ethical committee fol-
lowing national regulations.
Good Clinical Practice
Ethical conduct of the study
The study will be conducted according to the principles
of the Declaration of Helsinki (version 64th WMA Gen-
eral Assembly, Fortaleza, Brazil, October 2013) and in
accordance with the Dutch Medical Research Involving
Human Subjects Act (WMO). All personnel involved in
the conduct of this study has received training on GCP.
The principles of GCP will be followed throughout this
study. This study protocol follows the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) 2013 checklist (see Additional file 1).
Protocol amendments
All amendments will be notified to the accredited med-
ical ethical committee. Non-substantial amendments will
not be notified but will be recorded and filed by the in-
vestigator. Substantial amendments will not be imple-
mented until approval of the accredited medical ethical
committee has been obtained. Active participants will be
informed and a new informed consent procedure will be
started in the event of changes or additions to the proto-
col, which might influence participants’ decision to par-
ticipate in the study.
Confidentiality
All clinical and research data collected for this study will
be handled in such a way that participant confidentiality
is ensured. All digital and hard copy records are kept in
(digital) environments with limited access by appropriate
staff only. Access rights and responsibilities are recorded
on a designated list. Clinical information, images and re-
search data will not be used by the study staff for any
purposes other than the conduct of the study. Collec-
tion, sharing and maintenance of personal information
during and after the study will comply with the inter-
national and national rules and regulations.
Study record retention
At the end of the study, all data will be checked and put
into a validated database. Following Dutch national le-
gislation, the database will be closed anonymously and
stored in the Sponsor’s archive for 15 years.
Insurance and indemnity
The Sponsor has liability insurance and mandatory par-
ticipants insurance for medical research involving hu-
man participants, which is in accordance with the legal
requirements in the Netherlands (Article 7 WMO and
the Measure regarding Compulsory lnsurance for Clin-
ical Research in Humans of 2015).
Reporting publications and notification of results
Scientific publications
Anonymised results will be published in national and
international peer-reviewed journals.
Communication and dissemination
As the (inter)national expertise centre for NA, the Rad-
boudumc is key in forming treatment guidelines and in
the education of (peripheral) rehabilitation centres and
primary care. This position enables rapid transfer of
newly emerging knowledge on disease mechanisms and
treatment obtained through this trial to the medical
community. New treatment modalities, or adjusted or
improved rehabilitation programmes can therefore be
implemented rapidly.
Lay-friendly outcomes will be communicated to partic-
ipants through trial newsletters and with the broader pa-
tient population through patient organisations. Where
appropriate, information will be disseminated through
newsletters, websites and at conferences in collaboration
with patient organisations.
Authorship policy
Data arising from this study will be owned by the trial
team and their employer. Authorship of publications
coming from this study will follow the research code:
publications are submitted only with authors who have
made a substantial contribution to the research.
Peer review
The original proposal for the NA-CONTROL study has
been reviewed by external reviewers appointed by the
Prinses Beatrix Spierfonds, as part of the funding review
process.
Discussion
NA is a common peripheral nervous system disorder,
which leaves many patients with persistent scapular dys-
kinesia and resulting residual symptoms that greatly im-
pact quality of life for months to years after onset. To
date, there are no clinical trials targeting these debilitat-
ing residual symptoms, and no explanation as to why
these residual symptoms persist. The NA-CONTROL
study is the first trial to evaluate a rehabilitation
programme for residual symptoms after NA, that is fo-
cused on cerebral processes by relearning motor control
and self-management strategies. This programme has
been shown to increase functional capability of the
upper extremity in a pilot study of patients with NA.
The study design allows for comparison of the rehabili-
tation programme offered at the Radboudumc to usual
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care in patients with NA. Moreover, the lateralized na-
ture of this disorder allows the use of the unaffected,
contralateral upper extremity of patients with NA as an
additional within-patient control method.
The NA-CONTROL study will investigate the effect of
a specific rehabilitation programme on functional cap-
ability of the upper extremity. It thus aims to provide
evidence for a tailored intervention to reduce residual
complaints in NA. It additionally aims to provide insight
into the cerebral mechanisms that might underlie the
persistent motor problems in NA. This could confirm
the clinical intuition that peripheral nervous system dis-
orders (i.e. NA), may lead to maladaptive cerebral neuro-
plasticity, ultimately resulting in persistent symptoms,
such as impaired motor control. Moreover, it will dem-
onstrate whether such cerebral motor (mal)adaptations
associated with scapular dyskinesia can be targeted by a
specific rehabilitation programme. Knowledge on the ex-
tent of involvement of these cerebral mechanisms could
help guide how much and which aspects of existing
treatments should be focused on them. This knowledge
may greatly aid in the further development of mechan-
ism-based interventions for disturbed motor control in
NA and in other peripheral neurological disorders. The
NA-CONTROL study is an example of translational re-
search as it combines clinical and non-clinical expertise
and approaches.
Trial status
This study is based on the protocol dated 5 December
2017 and has the following version numbers:
NL63327.091.17–03 Algemeen Beoordelings-en Regis-
tratieformulier number (ABR-number) and 2017–3740
v3.0 Commissie Mensgebonden Onderzoek Arnhem-
Nijmegen (medical ethical committee). Patient recruit-
ment started in March 2018 and is ongoing at the time
of submission of this study protocol. Recruitment is ex-
pected to be completed by January 2020.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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